IMpower150: Clinical safety, tolerability and immune-related adverse events in a phase III study of atezolizumab (atezo) + chemotherapy (chemo) ± bevacizumab (bev) vs chemo + bev in 1L nonsquamous NSCLC
Martin Reck, Thomas Wehler, Francesco Orlandi et al. · Annals of Oncology · 2018
Background: Atezo (anti–PD-L1) + bev + chemo prolonged PFS and OS vs bev + chemo in patients (pts) with 1L nonsquamous NSCLC in the randomized Phase III IMpower150 study. This combination was well tolerated and its safety profile was consistent with known safety risks. This study further evaluates safety, tolerability and immune-related AEs by treatment phase.
Cited by 4 works. doi:10.1093/annonc/mdy292.009